PALI Stock News & Analysis | Latest Updates

PALISADES ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES

VANCOUVER, BC, Aug. 28, 2025 /CNW/ - Palisades Goldcorp Ltd. (TSXV: PALI) ("Palisades" or the "Company") is pleased to announce that at its meeting ("Meeting") of shareholders (the "Shareholders") held yesterday Shareholders approved the re-election of Gregor Gregersen and Elizabeth...

August 28, 2025Board Changes

PALI News

PALISADES ANNOUNCES RESULTS OF SHAREHOLDER MEETING AS WELL AS BOARD AND MANAGEMENT CHANGES

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

Palisade Bio Announces Topline Results From Phase 1 Studies Of PALI-2108; Phase 1 Program Met Primary Endpoints Of Safety, Tolerability And Pharmacokinetics

Brookline Capital Maintains Buy on Palisade Bio, Maintains $16 Price Target

Palisade Bio Q1 EPS $(0.47) Beats $(0.70) Estimate

Palisade Bio Presents Preclinical Data Highlighting Potential Of PALI-2108 As A Colon-Specific PDE4 Inhibitor For The Treatment Of Ulcerative Colitis And Other Inflammatory Bowel Diseases

Palisade Bio Announces It Will Present AI-Driven Approach To IBD Heterogeneity And Efficacy At 3rd Annual Precision Medicine In Inflammatory Bowel Disease Summit May13-15, 2025 In Boston, MA

Palisade Bio Announces Completion Of Dosing In Phase 1a Portion Of Ongoing Phase 1a/b Study Of PALI-2108 For Treatment Of Ulcerative Colitis

Palisade Bio Commences Dosing In Final Cohort Of Phase 1a/b Trial Of PALI-208 In Ulcerative Colitis

Palisade Bio To Present Data From Lead Program PALI-2108 At Digestive Disease Week 2025

Palisade Bio Announces Receipt Of CAD$1.39M Canadian SR&ED Credits For PALI-2108 Pre-Clinical Costs Under Joint Development With Giiant

Brookline Capital Initiates Coverage On Palisade Bio with Buy Rating, Announces Price Target of $38

Palisade Bio shares are trading higher after the company announced the presentation of data from two studios showing ex vivo bioactivation of PALI-2108 in the treatment of Ulcerative Colitis.

Palisade Bio Announces Announces Presentation Of Data From Two Studios Showing Ex Vivo Bioactivation Of PALI-2108 In Treatment Of Ulcerative Colitis

Palisade Bio's PALI-2108 Demonstrates Local Bioactivation And Dose Dependent Efficacy Response In Preclinical Mouse Models

Palisade Bio Granted U.S. Patent Titled 'Administration of serine protease inhibitors to the stomach'

Palisade Bio Provides Business Outlook And Highlights Expected Near-Term Pipeline Advancements